Home Newsfeeds Elanco Animal Health Says Made Immaterial Revisions Related To Some Sales Rebates And Discounts For Financial Statements For Year Ended Dec 31, 2022; Following Revisions, Previously Reported Q4 2022 Revenue Decreased From $988M To $985M

Elanco Animal Health Says Made Immaterial Revisions Related To Some Sales Rebates And Discounts For Financial Statements For Year Ended Dec 31, 2022; Following Revisions, Previously Reported Q4 2022 Revenue Decreased From $988M To $985M

– SEC Form 8 Filing

byHappy Mohamed

March 1, 2023

1 minute read

– SEC Form 8 Filing

News

Acer Therapeutics and Relief Therapeutics Announce That The China National Intellectual Property Administration (CNIPA) Issued Utility Model Patent 11,202,767 Covering ACER-001 Dosage Form

By Bill Haddad

July 8, 8:34 AM

Acer Therapeutics Inc. (NASDAQ:ACER) (Acer) and its collaboration partner, RELIEF THERAPEUTICS Holding SA ((SIX: RLF, OTCQB:RLFTF, RLFTY)) (Relief), today announced that the China National Intellectual Property

ACER

Morgan Stanley Maintains Equal-Weight on Five9, Lowers Price Target to $55

By Benzinga Newsdesk

November 8, 10:11 AM

Morgan Stanley analyst Meta Marshall maintains Five9 (NASDAQ:FIVN) with a Equal-Weight and lowers the price target from $75 to $55.

FIVN

These Analysts Boost Their Forecasts On Adobe After Upbeat Earnings

By Avi Kapoor

June 14, 8:46 AM

Adobe Inc. (NASDAQ:ADBE) posted upbeat results for its second quarter and also issued a strong forecast. Adobe reported…

ADBE

Ferrari CEO Sees Benefit From European Union’s Decision On Combustion Engines: Report

By Shivani Kumaresan

March 27, 12:57 PM

Ferrari NV (NYSE: RACE) Chief Executive Officer Benedetto Vigna has reportedly welcomed plans to exempt cars that operate on e-fuels from the European Union's planned 2035 phase-out of new combustion engine vehicles.

RACE

Elanco Animal Health Says Made Immaterial Revisions Related To Some Sales Rebates And Discounts For Financial Statements For Year Ended Dec 31, 2022; Following Revisions, Previously Reported Q4 2022 Revenue Decreased From $988M To $985M

Related Posts

Acer Therapeutics and Relief Therapeutics Announce That The China National Intellectual Property Administration (CNIPA) Issued Utility Model Patent 11,202,767 Covering ACER-001 Dosage Form

Morgan Stanley Maintains Equal-Weight on Five9, Lowers Price Target to $55

These Analysts Boost Their Forecasts On Adobe After Upbeat Earnings

Ferrari CEO Sees Benefit From European Union’s Decision On Combustion Engines: Report